Historically, Dominion Diagnostics’ research and development team developed analytical methods for highly sensitive and specific prescription drug monitoring and designer drug detection to keep up with the current trends. More recently, the research and development team at Dominion Diagnostics has designed a robust discovery testing menu missioned to provide laboratory services critical to the beginning phases in the drug discovery pathway.

The growing menu, launching as part of a new Dominion Discovery initiative, includes rapid, affordable and high quality pharmacokinetic (PK) method development and sample analysis. Also launching is a full menu of analytical drug development testing such as logD/logP, PAMPA, protein binding, plasma, microsome/S9 and recombinant CYP450 stability.

“The clinical development we do at Dominion is really rewarding,” shared Lawrence J. Andrade, Dominion Diagnostics Director of Research and Development. “It’s exciting to take our capabilities to another level and build new partnerships to expand both our expertise and national reach.”

Currently, Andrade leads the discovery efforts at Dominion Diagnostics and is actively collaborating with leading research institutions performing initial bioavailability small animal studies. And the company is making some real headway.

For example, a recent partnership with scientists at Roger Williams University in Rhode Island led to new findings. In June 2018, National Geographic featured these findings in an article titled “’Holy Grail’ Test for Illegal Cyanide-Caught Aquarium Fish May Be Fatally Flawed.” The article revealed issues with data used to detect thiocyanate. Thiocyanate is a byproduct of cyanide, which is illegally used to paralyze fish for easier capture.(https://news.nationalgeographic.com/2018/06/wildlife-watch-cyanide-test-marine-aquarium-fish/).

Ph.D., MS, and BS level scientists, who make up Andrade’s research and development team, share over 30 years of combined experience in GLP and cGMP regulated laboratories. They work across all phases of drug development. Alongside the new discovery menu, the team offers custom support and consulting for CRO teams. 

“We’re poised to become an extension of any research team tackling issues related to structural elucidation, stability indicating LC-MS/MS systems, cleaning verification, and more,” says Andrade.

Dominion’s fully automated research and development laboratory handles a high volume of samples efficiently. The lab uses several liquid chromatography tandem mass spectrometry (LC-MS/MS) platforms, including high-resolution accurate mass and triple quadrupole analyzers, coupled with ultra-performance liquid chromatography (UPLC). The LC-MS/MS method development and sample testing offer rapid turnaround times and affordability. Additionally, Dominion provides a formulation screen to help clients choose the best oral, IV, or injectable formulation for dosing solutions.

View our full test menu: https://domdiag.com/test-menu/